Advertising Disclaimer »
Tools and Links
Potential Clinical Advantages and Disadvantages of Different Formulations and Routes of Administration in Children1,2,5,43–47
Examples of Excipients With Elevated Toxicity and Safety Risks for (Preterm and Term) Newborns and Infants <6 Months of Age7,8,53–60
Examples of Recently Marketed/Prequalified Novel Oral Drug Formulations for Children97,104,108–116
3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, stavudine; EFV, efavirenz; FDA, US Food and Drug Administration; ODT, orodispersible tablet; PQ, prequalification; NVP, nevirapine; TFV, tenofovir.
Examples of Novel Drug Devices That Facilitate Oral Administration of Medicines in Children3,116,122
Thank you for your interest in spreading the word on Pediatrics.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.